Maca

Clinical Summary

Maca (Lepidium meyenii) is a Peruvian cruciferous root vegetable cultivated above 4,000 m in the Andes for ~2,000 years, consumed traditionally as both food and fertility aid. It is classified as an adaptogen in the supplement market.

The strongest clinical evidence supports improved subjective sexual desire in both sexes -- an effect that is hormone-independent (multiple RCTs confirm no change in serum testosterone, estradiol, FSH, or LH; PMID 12472620, 12525260, 18784609). This is a critical nuance: maca is widely marketed as a "testosterone booster," but this claim is thoroughly debunked by replicated null findings across multiple studies (SR: PMID 37697053).

Secondary evidence supports modest improvement in sperm quality parameters (MA: PMID 36110519), SSRI-induced sexual dysfunction (Phase 3 RCTs from MGH: PMID 18801111; NCT00568126), and menopausal mood/anxiety symptoms (small RCTs: PMID 18784609, 24931003). All human evidence is limited by small sample sizes (N=14-80).

Three maca colors have distinct phytochemical profiles and partially distinct effects in preclinical models: black (cognition, spermatogenesis), red (prostate, bone), and yellow (most common, broadest but mildest profile). Human head-to-head color comparisons are nearly nonexistent.

Active compounds include macamides (FAAH inhibitors -- endocannabinoid modulation), macaenes, glucosinolates, alkaloids (lepidilines), and polysaccharides. The FAAH inhibition pathway (PMID 39585076) is the most promising mechanistic lead for explaining hormone-independent effects on sexual function and mood.

Safety profile is favorable: no serious adverse events in any clinical trial, traditional food-level consumption for millennia, and FAERS data shows zero reports where maca is the suspect drug (all concomitant noise). Main theoretical concern is glucosinolate (goitrogen) content in raw maca affecting thyroid function, though no clinical thyroid dysfunction has been reported in trials. Gelatinization partially reduces goitrogen content.

Product quality is a significant concern: Independent testing found ~50% of commercial maca products lacked detectable levels of key active compounds, and one product was adulterated with thiosildenafil (a sildenafil analogue).

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal-to-human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal-to-human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal -- see Safety section | AVOID Contraindicated for this specific indication

Star rating legend:

Sexual desire: The most consistent finding across maca research. Multiple RCTs from Peru, Korea, Italy, and Australia show improved self-reported desire at 8-12 weeks. Critically, this occurs WITHOUT changes in circulating hormones -- the mechanism appears to involve FAAH inhibition (endocannabinoid tone modulation) rather than androgen pathways. The 2024 SR (PMID 37697053) explicitly concluded maca is not a testosterone booster.

Sperm quality: Meta-analysis (PMID 36110519) pooled limited RCTs and found modest improvements in concentration and motility. GRADE-equivalent evidence quality rated LOW. The Czech/Peruvian RCT (PMID 34585449) found improved motility but not concentration. Black maca appears more active than other colors for spermatogenesis in preclinical models.

Color-specific effects: Black maca shows the strongest preclinical signal for cognition and spermatogenesis. Red maca for prostate size reduction and bone preservation. Yellow maca is the most commercially available but potentially the least potent for specific indications. Very few human studies have compared colors head-to-head -- the RCT by Gonzales-Arimborgo et al. (PMID 27548190, N=175) compared black and red maca and found both well-tolerated with modest effects.

Prescribing

Dosing Table

Formulation Table

Formulation note: Gelatinization is a heat/pressure process that removes starch and partially breaks down glucosinolates (goitrogens). It does NOT involve gelatin -- the product remains plant-based. Most clinical trials used simple dried root powder, not standardized extracts.

Safety

Interactions Table

Contraindications

• Hormone-receptor-positive cancers: Theoretical concern due to plant sterol content and in vitro MMP-1 stimulation in triple-negative breast cancer cells (PMID 33560149). No clinical evidence of harm, but precautionary avoidance warranted until clarified.
• Active thyroid disease (Hashimoto's, Graves'): Raw maca contains glucosinolates; use gelatinized form and monitor TPO antibodies/TSH. No clinical thyroid dysfunction reported in trials, but theoretical goitrogenic effect exists.
• Pregnancy/lactation: Insufficient safety data. Traditional Peruvian use during pregnancy exists, but no controlled trials. Avoid until data emerges.

Adverse Effects (ranked by frequency from trials + community reports)

1. GI distress (bloating, gas, cramping) -- common (~15-20%), especially with raw maca. Usually resolves in 1-2 weeks or with switch to gelatinized.
2. Insomnia/sleep disruption -- occasional (~10%), dose- and timing-dependent. Take before 2 PM.
3. Acne/skin changes -- occasional (~10-15%), polarized (some report improvement, others worsening). More common in women.
4. Mood changes (irritability, mood swings) -- occasional (~5-10%). More commonly reported by women. May resolve with dose reduction.
5. Headache -- occasional (~5%). Usually transient, first week.
6. Jitteriness/overstimulation -- occasional (~5-10%), dose-dependent. Reduce dose.
7. Menstrual cycle changes (spotting, shifted timing) -- moderate in women (~15-20%), first 1-2 months. May not normalize in all users.
8. Palpitations/tachycardia -- rare (~3%). Reduce dose; discontinue if persistent.

FAERS Signal Table (from BioMCP)

FAERS interpretation: 161 total reports for "maca" + 32 for "Lepidium meyenii." In ALL cases, maca was listed as a concomitant medication, never as the suspect drug. Zero attributable safety signals. The reported reactions (fatigue, headache, ED) are attributable to the primary suspect drugs in those reports (sodium oxybate, dupilumab, infliximab, quetiapine, etc.). This is typical FAERS noise for supplements.

Monitoring Table

Special Populations

Thyroid Disease

Synergies & Stacking

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

No known pharmacogenomic modifiers for maca. Zero publications exist on genetic variants affecting maca response, CYP interactions, or metabolizer status. This is a complete data gap.

Theoretical considerations (unvalidated):

• COMT (Val158Met): Maca's FAAH inhibition affects endocannabinoid tone, which interacts with catechol metabolism. Val/Val individuals might respond differently. Speculative.
• CYP enzymes: No CYP interaction data exists for maca. Unknown whether maca inhibits or induces any CYP isoforms.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities (Reddit, Longecity, WebMD, iHerb, Acne.org, The Maca Team). None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Mixed-to-Positive across ~500-800 aggregated reports. Roughly 55-60% positive, 15-20% neutral/no effect, 20-25% negative or mixed. The supplement is polarizing -- users either notice clear effects or nothing at all.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: No. Sold through conventional supplement channels (NOW Foods, Nootropics Depot, The Maca Team, iHerb brands).
• Influencer concentration: Moderate concern. The Maca Team is both the largest retailer AND most prolific content producer -- inherent conflict of interest. Content is sourced but systematically positive.
• Astroturfing signals: Low. Forum discussions appear organic with genuine negative reviews present.
• Commercial bias: Significant. Majority of educational maca content comes from sellers. Independent assessors (Examine.com, ConsumerLab) are more conservative.
• Product quality alert: ~50% of tested products lacked key active compounds; one contained thiosildenafil. Third-party CoA verification is critical.

Folk vs Clinical Reality Check

Community experience aligns with clinical data on: libido improvement (the most consistent claim), hormone-independence (experienced users know it doesn't raise T), and GI side effects (raw > gelatinized). Community experience diverges on: testosterone boosting (still widely marketed despite clinical null), hair regrowth (zero clinical evidence), female fertility (no human data), and color-specific effects (strong beliefs with minimal human comparison data). Most likely explanations: placebo effect (hair/fertility), marketing persistence despite evidence (testosterone), and animal-to-human extrapolation of color-specific preclinical data.

Deep Dive: Mechanisms & Research

Key Mechanisms

1. FAAH Inhibition / Endocannabinoid Modulation (PMID 39585076) Macamides are structural analogues of anandamide and inhibit fatty acid amide hydrolase (FAAH), increasing endocannabinoid tone. This is the most promising mechanistic explanation for maca's effects on sexual desire, mood, and neuroprotection without hormonal changes. The endocannabinoid system modulates reward, motivation, and pain -- pathways relevant to libido and well-being.

2. Serotonin Synthesis via Gut-Brain Axis (PMID 38867934) Chinese research (2024) demonstrated maca-derived extracellular vesicles promote serotonin synthesis through gut-brain axis modulation. Novel mechanism potentially explaining antidepressant-like and anxiolytic effects.

3. Anti-Inflammatory / Antioxidant (PMID 39334705) Systematic review confirmed maca reduces oxidative stress biomarkers (SOD up, MDA down, GSH up). Population study in Peruvian highlands found lower IL-6 in maca consumers (PMID 23934543). Macamides reduce inflammatory markers during exercise (PMID 35026191).

4. Mitochondrial Protection (PMID 33729250) Maca prevents mitochondria-mediated muscle damage during exercise. Relevant to anti-fatigue and exercise performance effects.

5. Androgen/Estrogen Receptor Modulation (PMID 29375645) Red maca's prostate-protective effects appear to involve direct receptor modulation rather than circulating hormone changes -- consistent with the hormone-independence of maca's effects.

6. Myogenic Differentiation / Anti-Atrophy (PMID 38340399) Korean research (2024) showed macamide enhanced myogenic differentiation via AKT/p38 and attenuated dexamethasone-induced muscle atrophy. Relevant to sarcopenia.

Color-Specific Phytochemistry (PMID 38398854)

Clinical Trials (from BioMCP / ClinicalTrials.gov)

East Asian registries: KCT0006415 (Korea) -- Maca in Late-Onset Hypogonadism, DB-RCT, N=80, 3 g/d x 12 wk. Published as PMID 36593713.

Regulatory Status

• FDA: Not approved as drug. Dietary supplement under DSHEA (1994). GRAS as food.
• EMA: No European herbal monograph from EMA/HMPC. Not an approved medicinal product.
• TGA (Australia): Permitted for Listed Medicines (Class 1, low risk) since 2006.
• Health Canada: NHP monograph exists; permitted for traditional use claims.
• WADA: Not on 2026 Prohibited List.
• Regulatory context: Maca is primarily a food crop with no patent protection, so no commercial incentive for NDA-track trials. "Not FDA-approved" reflects market economics, not a safety signal. Peru protects maca as national patrimony (Law 28477, 2005).

Ataraxia Verdict (as of 2026-04-16)

Evidence Classification (Mode 5: Evidence Classifier)

Synthesized view in Indications & Evidence table above (Type + BH + Safety columns). Detailed rationale below.

Hype Check (Mode 1: Fallacy Radar)

• Appeal to tradition: "Used for 2,000 years in Peru" is true but does not validate therapeutic claims at supplement doses. Traditional use was as food, not targeted therapy.
• Appeal to nature: "Just a root vegetable" does not guarantee efficacy or eliminate dose-dependent effects.
• Hasty generalization: Animal-to-human extrapolation is pervasive for cognition, prostate, and bone claims.
• Cherry-picking: Color-specific marketing selects the best preclinical result per color without noting absent human confirmation.
• Testosterone booster myth: The single largest misinformation issue. Multiple RCTs and a systematic review confirm maca does NOT raise testosterone, yet marketing persists.
• Argument from popularity: "Millions of Peruvians eat it" -- as a food at altitude, not as capsules for ED at sea level.

Evidence Gaps

• No human RCTs for cognition, bone, hepatoprotection, metabolic, or dermatological endpoints
• No pharmacokinetic studies in humans (ADME unknown)
• No pharmacogenomic data (complete gap)
• No head-to-head trials vs active comparators
• No long-term safety data beyond 4 months
• No formal dose-response study beyond 1.5 g vs 3 g pilot
• No human color-comparison RCTs beyond PMID 27548190
• No female fertility data from maca-only studies

Bias Flags (Mode 4: First Principles)

• What survives: Subjective sexual desire improvement (replicated Peru, Korea, Italy, Australia). Hormone-independence (replicated null). Favorable safety up to 4 months.
• What doesn't: Testosterone boosting (debunked). Hair growth (zero evidence). Female fertility (no human data). Bone density (animal only).
• Dosing basis: 1.5-3 g/d is RCT-supported. Higher community doses (6-20 g) are untested.
• Cui bono: Peruvian export industry, supplement retailers, content-producing sellers benefit from positive framing. No pharma competitor suppressing research.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: "Testosterone booster" labeling persists on retail products despite replicated null findings. "Clinical strength" claims on products that may lack active compounds.
• Influencer economics: The Maca Team dominates educational content AND sells the product -- textbook conflict. No single major influencer dominates (unlike some nootropics).
• Counter-narrative manipulation: No significant pharma FUD detected. Maca is not commercially threatening enough to attract active suppression.
• Cui bono summary: Pro-maca: Peruvian export economy ($50M+), supplement retailers, Amazon sellers. Anti-maca: no significant actor. This asymmetry (motivated promotion, unmotivated opposition) suggests net hype inflation.
• Red team highlight: Product quality is the most concerning angle. ~50% of products may lack active compounds. Users attributing effects to "maca" may be experiencing placebo; users saying "maca doesn't work" may have taken inert products. This confounds all evidence, clinical and anecdotal.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 5/10 -- moderate evidence clustered around a narrow set of indications (sexual desire, SSRI-induced sexual dysfunction, male fertility); no indication yet reaches 4/5 and better-studied alternatives exist for most individual uses.
• Opportunity cost: ~$15-30/month, 1-3 daily servings, possible GI adjustment. Better-studied alternatives exist for most individual indications (PDE5 inhibitors for ED, zinc/folate for fertility).
• Verdict: WATCH LIST -- promising for sexual desire and male fertility with favorable safety, but evidence quality remains LOW-MODERATE. No indication reaches 4/5. Revisit when larger RCTs report (NCT02624648 N=144, NCT05891327 N=60).
• Conditions for upgrade to ADD: (1) Large independent RCT replicates MGH findings, OR (2) personal SSRI-induced SD where maca has Phase 3 data, OR (3) male fertility goal with semen analysis tracking.

Bottom Line

Maca is a well-tolerated adaptogen with the strongest (though still modest) evidence for improving subjective sexual desire independently of hormones, and some support for sperm quality and menopausal mood symptoms. It is NOT a testosterone booster -- this is the most persistent myth and most clearly debunked claim. Safety is clean: no serious trial AEs, no attributable FAERS signals, millennia of food use. The biggest real-world risk is product quality -- buy third-party tested with CoA. For most other marketed indications (cognition, bone, prostate, energy), evidence remains preclinical. The FAAH inhibition mechanism is the most interesting research lead. WATCH LIST: revisit in 12 months.

Practical Notes

Brands & Product Selection

Quality is the single biggest practical concern.

Quality markers:

• Third-party testing (NSF, USP, ConsumerLab certified)
• Certificate of Analysis (CoA) available per batch
• Organic certification (Peru is primary origin)
• Macamide content declared if standardized extract
• Color specified (black, red, or yellow)
• Gelatinized clearly labeled

Red flags:

• "Testosterone booster" on label
• No CoA available
• Unrealistically low price
• Proprietary blend hiding actual maca content

Storage & Handling

• Cool, dry, dark place. Sealed container. Shelf life 2-3 years.
• No refrigeration needed.
• Gelatinized powder more shelf-stable than raw (starch removed).
• Degradation indicators: off smell, clumping, color change.

Palatability & Compliance

• Earthy, malty, butterscotch-like taste. Polarizing.
• Mixes well into smoothies, oatmeal, coffee, hot chocolate.
• Gelatinized tastes milder and mixes more easily.
• Capsules eliminate taste -- best for compliance if taste is an issue.
• Habit stacking: pair with morning coffee/smoothie ritual.

Exercise & Circadian Timing

• Take morning or early afternoon. Community reports of insomnia with evening dosing.
• Pre-workout: 30-45 min before exercise (Taiwan RCTs used this timing).
• No established circadian interaction.

Reference Ranges (Expected Biomarker Changes)

Cost

What We Don't Know

• Mechanism of sexual desire enhancement -- FAAH inhibition is the leading hypothesis but unvalidated in humans
• Optimal color for each indication -- preclinical data suggests color matters but human comparisons nearly nonexistent
• Long-term safety beyond 4 months -- no controlled data past this window
• Pharmacokinetics -- ADME of macamides in humans unstudied
• Pharmacogenomics -- zero data on genetic modifiers of response
• Female fertility -- no maca-only human trials despite widespread marketing
• Cognition in humans -- strong preclinical signal but zero human trials
• Dose-response curve -- only one pilot compared 1.5 g vs 3 g
• Product bioequivalence -- whether "3 g maca" means the same thing across products is unknown
• Thyroid threshold -- glucosinolate concern is theoretical, never observed clinically
• Cancer safety -- MMP-1 stimulation in TNBC cells (PMID 33560149); clinical significance unknown
• Interaction with hormone therapies -- no data on HRT, TRT, or hormonal contraceptives

References

Systematic Reviews & Meta-Analyses

• PMID 39796542 -- Huerta Ojeda et al. (2024). Maca on physical performance: SR & MA. Nutrients. Animal evidence strong; human limited.
• PMID 39334705 -- (2024). Maca on cellular oxidative stress: SR & MA. Reduces oxidative stress biomarkers.
• PMID 37697053 -- (2024). Do testosterone boosters increase serum T? SR. Maca does NOT raise testosterone.
• PMID 41696741 -- Ho CY et al. (2026). Herbal supplements for ED: SR & MA. J Tradit Complement Med.
• PMID 36110519 -- Lee HW et al. (2022). Maca on semen quality: SR & MA. Front Pharmacol. Modest improvement; LOW quality.
• PMID 29633089 -- Borrelli et al. (2018). Herbal supplements for ED: SR & MA. Drugs. Suggestive but not conclusive.
• PMID 34552783 -- (2021). Herbal remedies for ED: SR. Preliminary promise.
• PMID 27621241 -- Lee MS et al. (2016). Maca to improve semen quality: SR. Maturitas.
• PMID 21840656 -- Lee MS et al. (2011). Maca for menopausal symptoms: SR. Maturitas. Insufficient evidence.
• PMID 20691074 -- Shin BC et al. (2010). Maca for sexual function: SR. BMC Complement Altern Med.
• PMID 30156931 -- Najaf Najafi M et al. (2018). Phytoestrogens on sexual function in menopause: SR & MA.
• PMID 31630610 -- Shahmohammadi et al. (2019). Herbal medicines on anxiety/depression in menopause: SR & MA.

Landmark RCTs

• PMID 36593713 -- Shin D et al. (2023). Maca in late-onset hypogonadism: DB-RCT N=80, Korea. Improved AMS, IIEF, IPSS; no T change. World J Mens Health.
• PMID 12472620 -- Gonzales GF et al. (2002). Maca on sexual desire: RCT N=57. Increased desire at 8 wk. Andrologia.
• PMID 18801111 -- Dording CM et al. (2008). Maca for SSRI-induced SD: pilot N=20. 3 g > 1.5 g. CNS Neurosci Ther.
• PMID 19260845 -- Zenico T et al. (2009). Maca in mild ED: RCT N=50. Andrologia.
• PMID 18784609 -- Brooks NA et al. (2008). Maca in postmenopausal women: RCT N=14. Reduced anxiety/depression. Menopause.
• PMID 24931003 -- Stojanovska L et al. (2015). Maca reduces BP and depression in postmenopausal women: pilot N=29.
• PMID 27548190 -- Gonzales-Arimborgo C et al. (2016). Black/red maca safety/efficacy: RCT N=175.
• PMID 34585449 -- (2021). Maca in infertile patients: RCT. Improved motility, not concentration.
• PMID 40960048 -- (2025). Maca on basketball performance: DB crossover N=10, Taiwan.
• PMID 39781531 -- (2025). Maca and IFN-gamma after exercise: DB-RCT, Taiwan.
• PMID 18054420 -- (2008). Maca safety: 3 g/d x 4 mo, no adverse effects on liver/kidney/blood.
• PMID 12525260 -- Gonzales GF et al. (2003). Maca does not affect reproductive hormones in men.

Mechanism & Phytochemistry

• PMID 39585076 -- (2024). Macamides: FAAH inhibitors and neuroprotective agents. Review.
• PMID 38867934 -- (2024). Maca EVs ameliorate depression via gut-brain 5-HT. iMeta. China.
• PMID 33288191 -- (2020). Macamides comprehensive review. Food Res Int.
• PMID 34533247 -- (2021). Active components of maca. Phytother Res.
• PMID 38398854 -- (2024). Not all maca is created equal: color-specific effects.
• PMID 38440178 -- (2024). Comprehensive maca safety/efficacy review.
• PMID 29375645 -- (2018). Red maca and androgen/estrogen receptor modulation.
• PMID 33729250 -- (2021). Maca prevents mitochondria-mediated muscle damage.
• PMID 35026191 -- (2022). Macamides reduce inflammatory markers in exercise.
• PMID 38340399 -- (2024). Macamide and myogenic differentiation via AKT/p38. Korea.
• PMID 34606547 -- (2021). Macamide protects hippocampal neurons.
• PMID 17543435 -- (2007). Black maca improves memory in mice.
• PMID 41154523 -- (2025). Black maca neuroprotective effects.
• PMID 40609940 -- (2025). Maca polysaccharides + gut microbiota.
• PMID 24333960 -- (2014). Maca enhances LH in OVX rats. Japan.
• PMID 37278859 -- (2023). Maca polysaccharides inhibit alpha-glucosidase.

Disease-Specific Studies

• PMID 15661081 -- (2005). Red maca reduces prostate size (rats).
• PMID 17289361 -- (2007). Red maca prevents prostate hyperplasia (rats).
• PMID 18477205 -- (2008). Red maca and BPH (rats).
• PMID 20616517 -- (2010). Red maca preserves bone in OVX rats.
• PMID 35932411 -- (2022). Red maca prevents liver toxicity (rats).
• PMID 39368558 -- (2024). Maca polysaccharides mitigate aflatoxin liver toxicity.
• PMID 21781063 -- (2011). Maca leaf UVB photoprotection (mice).
• PMID 28846044 -- (2017). Red maca wound healing.
• PMID 37107174 -- (2023). Fermented maca anti-melanogenic. Korea.
• PMID 34765511 -- (2021). Maca + soy isoflavones reduce cardiac ischemia-reperfusion injury.
• PMID 23934543 -- (2013). Population study: maca consumers have lower IL-6. Peru.
• PMID 33049880 -- (2020). Maca polysaccharides re-educate tumor macrophages.
• PMID 41097111 -- (2025). Maca promotes salivary gland regeneration. Taiwan.
• PMID 41472815 -- (2025). Bee pollen + maca and gut microbiota in BPH rats.
• PMID 34831102 -- (2021). Maca prevents muscle atrophy (zebrafish). Korea.
• PMID 33560149 -- (2021). CAUTION: MMP-1 stimulation in TNBC cells.
• PMID 41302419 -- (2025). Lepidilines: anticancer vs neuroblastoma.
• PMID 39047879 -- (2024). HIV inhibition via maca alkaloids.
• PMID 31798745 -- (2019). Vitex + maca + folate for female fertility (combination).
• PMID 40032845 -- (2025). Maca dentifrice and enamel remineralization.
• PMID 39409148 -- (2024). Maca as cosmetic ingredient.

Safety & Interactions

• PMID 37829299 -- (2023). Adaptogen-antidepressant interactions: no serious maca interactions.
• PMID 31884156 -- (2020). Safety evaluation: ethanolic extract safe in rodents.
• PMID 33066617 -- (2020). Herbal sexual enhancers: maca among safer options.
• PMID 24730393 -- (2014). Antidepressant-like activity of maca in stress models.

Bibliometric & Cultural

• PMID 40165997 -- (2025). Bibliometric analysis of global maca research. China.
• PMID 34087032 -- (2021). Lignans from maca with anti-inflammatory activity. China.